DECENTRALISED CLINICAL TRIALS AND THE FUTURE


likely to utilise decentralisation. But in recent years, growth has been particularly strong for Phase II trials, which now make up one in every two trials with a decentralised approach. Finally, commercial sponsors used to lead most decentralised trials. But during the past decade, growth has been strongest for academic institutions.


DCT adoption tracker: the analysis While COVID-19 lockdown measures made decentralisation an obvious answer to keep clinical trials running, the response was not immediate. As the pandemic started, disruption to new non-COVID-19 trials was severe across the board, regardless of whether the trial had a decentralised element. March 2020 became  1,000 new non-COVID-19 trials were initiated. But the same month also marked the  In previous years, around 5% of all trials had used decentralisation components. By April 2020, 8% of the 250 new COVID-19 trials were   to be a hotspot for decentralisation for the remainder of 2020 and throughout 2021.


“While lockdown measures caused by the pandemic made decentralisation an obvious answer to keep clinical trials running, the response was not immediate”


As non-COVID-19 trial activity recovered  of decentralisation began to spread to other disease areas. Integration of decentralised elements in trials has been particularly fast for research into the central nervous system, where 15% of trials started since the beginning of 2021 have used decentralised components.


DCT uptake according to disease To dig deeper and examine how the use of different forms of decentralisation varies by disease area and even by organisation, we took GlobalData’s subcategorisations of decentralisation and created six groups, each reflecting a distinct form of remote or digital


Outsourcing in Clinical Trials Handbook | 79


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100